Event-Driven Stocks

Eledon Pharmaceuticals, Inc.

ELDNNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue——————
Operating income——−$43.0M−$88.4M−$36.9M−$18.5M
Net income−$45.6M−$36.2M−$116.5M−$88.0M−$34.5M−$22.8M
Total assets$169.0M$177.4M$89.1M$92.8M$170.5M$197.2M
Total liabilities$32.2M$59.3M$81.9M$8.6M$6.6M$6.6M
Equity$81.1M$62.4M−$48.5M$84.2M$164.0M$190.6M
EPS (diluted)$-0.52$-0.66$-4.73$-6.16$-2.33—
Shares out.59.9M24.8M13.8M14.3M14.3M16.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−56.3%
Return on assets
−27.0%
Return on capital (ROCE)
—
Liabilities / assets
19.1%
Debt / equity
0.40×
Book value / share
$1.35
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
9.9%moderate
Piotroski F-Score
1/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
42
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 33Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 1 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
6 acquisitions0 disposalsnet +25,725 shares · last 6
InsiderDateTypeSharesPrice
Mcbride John S.DirectorJan 10, 2026Option exercise3,430$0.00
Hillson JanDirectorJan 10, 2026Option exercise3,430$0.00
Kirk AllanDirectorJan 10, 2026Option exercise3,430$0.00
Katkin KeithDirectorJan 10, 2026Option exercise8,575$0.00
Lee JuneDirectorJan 10, 2026Option exercise3,430$0.00
Robinson James A. Jr.DirectorJan 10, 2026Option exercise3,430$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20266.8M5.4-10.2%
Apr 30, 20267.6M3.6-3.3%
Apr 15, 20267.8M6.2+8.6%
Mar 31, 20267.2M4.2-14.5%
Mar 13, 20268.4M6.5+30.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)